Why Is Protalix BioTherapeutics Stock Falling On Friday?

All NewsOctober 17, 2025

EMA issues a negative opinion on Protalix and Chiesi’s Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent